Results 21 to 30 of about 71,664 (187)
, 2019 A. Overall structure of HER2-trastuzumab-pertuzumab. Domain I through domain IV of HER2 are shown in green, teal, cyan, and blue respectively. Trastuzumab Fab and pertuzumab Fab are shown in pink and yellow respectively.
Yue Hao (1261215) +4 more
core +1 more source
HER2 testing in breast cancer: Opportunities and challenges [PDF]
, 2006 Human epidermal growth factor receptor 2 (HER2) is overexpressed in 15-25% of breast cancers, usually as a result of HER2 gene amplification. Positive HER2 status is considered to be an adverse prognostic factor. Recognition of the role of HER2 in breast
Lebeau, Annette, Annette Lebeau
core +1 more source
, 2023 (A) B14.3 HER2 cells were cultured in the presence of Trastuzumab for 48h and tumor cell proliferation was measured in the MTS assay. (B) Expression of human HER2 was determined by flow cytometry on B14.3 HER2 cells retrieved from 3 representative mouse ...
Kam Zaki (8907518) +4 more
core +1 more source
Engineering peptides into antibodies—opportunities and strategies for therapeutic innovation
FEBS Letters, EarlyView.Peptides and antibodies occupy complementary therapeutic niches. Peptides recognize difficult targets in a compact format, while antibodies add specificity, long half‐life, and effector functions. This review examines strategies that merge both modalities—peptide grafting into loops, terminal and Fc fusions, and bioconjugation—highlighting how ...
Jinling Wang +2 more
wiley +1 more source
Cryo-EM map of HER2-trastuzumab-pertuzumab.
, 2019 A. Cryo-EM map showing the three components of the ternary complex: HER2 (sky blue), trastuzumab Fab (pink), and pertuzumab Fab (orange). B. Local resolution analysis of the final construction calculated using ResMap. C. Final construction (grey surface)
Yue Hao (1261215) +4 more
core +1 more source
An integrated model of the transcriptome of HER2-positive breast cancer [PDF]
, 2013 Our goal in these analyses was to use genomic features from a test set of primary breast tumors to build an integrated transcriptome landscape model that makes relevant hypothetical predictions about the biological and/or clinical behavior of HER2 ...
Melissa Lau +65 more
core +1 more source
Advanced Materials for Biologics Delivery to Brain Tumors
Advanced Materials, EarlyView.Material innovation is central to unlocking the therapeutic potential of biologics against many central nervous system diseases, including brain cancer. By engineering carriers with controlled transport, targeting, and release properties, advanced materials can overcome the blood–brain barrier and tumor microenvironment, improving the delivery of ...
Yuran Feng +4 more
wiley +1 more source
The role of receptor tyrosine kinase signalling in HER-2-positive cells and trastuzumab (Herceptin) resistance in breast cancer [PDF]
, 2009 HER-2 gene amplification or overexpression occurs in approximately 25 % of breast cancers, and trastuzumab (Tmab) is a monoclonal antibody currently used to treat patients with HER-2-overexpressing breast cancer.
Browne, Brigid
core +2 more sources
Toward Personalized Theranostics: A Modular PET Platform for Antibody‐Based Imaging and Therapy
Advanced Science, EarlyView.This modular, site‐specific antibody platform enables customizable conjugates for PET imaging and therapy. Interchangeable payloads – including radiometals, cytotoxics, and fluorophores – support adaptable, multimodal applications with limited off‐target effects. In vivo, the DFO/DOTAGA bischelate immunoconjugate provided clear tumor delineation in PET/
Delphine Vivier +16 more
wiley +1 more source
Trastuzumab Deruxtecan versus Trastuzumab Emtansine for Breast Cancer
, 2022 Background: Trastuzumab emtansine is the current standard treatment for patients with human epidermal growth factor receptor 2 (HER2)-positive metastatic breast cancer whose disease progresses after treatment with a combination of anti-HER2 antibodies ...
Junichiro Watanabe +191 more
core +3 more sources